SARS-CoV-2-IgM/IgG-Test-Kit(Immunochromatographic-Assay) |
EGIVD008 |
EnoGene |
CE-recogniton-IVD |
EUR 350 |
Description: CE recogniton IVD |
Human IgG antibody Laboratories manufactures the sars cov rna pcr test reagents distributed by Genprice. The Sars Cov Rna Pcr Test reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Sars products are available in stock. Specificity: Sars Category: Cov Group: Rna Pcr
COX (Coxsackievirus Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of COX (Coxsackievirus Antibody IgG) |
RV (Rubella Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of RV (Rubella Antibody IgG) |
CMV (Cytomegalovirus Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of CMV (Cytomegalovirus Antibody IgG) |
ACA (Anticardiolipin Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of ACA (Anticardiolipin Antibody IgG) |
TOX (Toxoplasma Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of TOX (Toxoplasma Antibody IgG) |
ANA (Antinuclear Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of ANA (Antinuclear Antibody IgG) |
SARS-CoV-2 Rapid Antigen Test Nasal |
Roche Diagnostics |
25 Tests/Kit |
EUR 112.8 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Rna Pcr information
SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp) , Active |
REC31874-10 |
The Native Antigen Company |
0.01 |
EUR 622.57 |
Description: Recombinant full-length SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) was expressed in E. coli cells using a C-terminal His-tag. |
SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp) , Active |
REC31874-20 |
The Native Antigen Company |
0.02 |
EUR 1167.32 |
Description: Recombinant full-length SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) was expressed in E. coli cells using a C-terminal His-tag. |
SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp) , Active |
REC31874-50 |
The Native Antigen Company |
0.05 |
EUR 2460.93 |
Description: Recombinant full-length SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) was expressed in E. coli cells using a C-terminal His-tag. |
RNA Polymerase, FLAG-tag (SARS-CoV-2) |
100729 |
BPS Bioscience |
100 µg |
EUR 350 |
Description: Severe acute respiratory Coronavirus 2 RNA dependent RNA polymerase, GenBank Accession No. YP_00972530, a.a. 1-932(full length), with an N-terminal FLAG-tag expressed in a HEK293 expression system. MW=108 kDa. |
SARS-CoV-2 Antibody (NSP12 / RNA polymerase) |
RQ6306 |
NSJ Bioreagents |
100 ug |
EUR 390.15 |
Description: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). Virus particles include the RNA genetic material and structural proteins needed for invasion of host cells. Once inside the cell the infecting RNA is used to encode structural proteins that make up virus particles, nonstructural proteins that direct virus assembly, transcription, replication and host control and accessory proteins whose function has not been determined.~ ORF1ab, the largest gene, contains overlapping open reading frames that encode polyproteins PP1ab and PP1a. The polyproteins are cleaved to yield 16 nonstructural proteins, NSP1-16. Production of the longer (PP1ab) or shorter protein (PP1a) depends on a -1 ribosomal frameshifting event. The proteins, based on similarity to other coronaviruses, include the papain-like proteinase protein (NSP3), 3C-like proteinase (NSP5), RNA-dependent RNA polymerase (NSP12, RdRp), helicase (NSP13, HEL), endoRNAse (NSP15), 2'-O-Ribose-Methyltransferase (NSP16) and other nonstructural proteins. SARS-CoV-2 nonstructural proteins are responsible for viral transcription, replication, proteolytic processing, suppression of host immune responses and suppression of host gene expression. The RNA-dependent RNA polymerase is a target of antiviral therapies. |
anti- SARS antibody |
FNab07609 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against SARS |
SARS CoV E Protein |
abx060650-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] |
BSV-COV-AB-01 |
BioServUK |
25 ul |
Ask for price |
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal) |
SARS CoV Nucleocapsid Protein |
abx060652-1mg |
Abbexa |
1 mg |
EUR 2247.6 |
|
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] 100 ul |
BSV-COV-AB-02 |
BioServUK |
100 ul |
Ask for price |
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal) |
OAEF00177-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
OAEF00177-1MG |
Aviva Systems Biology |
1mg |
EUR 471 |
|
OAEF00179-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
OAEF00179-1MG |
Aviva Systems Biology |
1mg |
EUR 471 |
|
OAEF00193-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
OAEF00193-1MG |
Aviva Systems Biology |
1mg |
EUR 471 |
|
OAEF00194-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
OAEF00194-1MG |
Aviva Systems Biology |
1mg |
EUR 471 |
|
OAEF00195-1MG - Coronavirus (COVID-19) (SARS-CoV-2) (SARS-CoV NP) Antibody |
OAEF00195-1MG |
Aviva Systems Biology |
1mg |
EUR 471 |
|